Jennison Associates
GILD icon

Jennison Associates’s Gilead Sciences GILD Stock Holding History

Jennison Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-365,000
Closed -$27.4M – 754
2013
Q4 		$27.4M Hold
365,000
– – 0.03% 412
2013
Q3 		$22.9M Buy
365,000
+345,000
+1,725% +$20.6M 0.02% 423
2013
Q2 		$1.02M Buy
+20,000
New +$1.04M ﹤0.01% 589

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates's GILD Position: Q2 2026 in Review

Jennison Associates sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1,264,546 shares — an estimated $176M sold.

Jennison Associates first reported a position in GILD in Q2 2013 and held it in 23 quarters. The position peaked at $1.52B in Q3 2013. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Jennison Associates reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Jennison Associates sold 1,264,546 Gilead Sciences shares in Q2 2026, an estimated $176M.
  • Jennison Associates first reported a position in Gilead Sciences in Q2 2013 and held it in 23 quarters.
  • Jennison Associates's Gilead Sciences position peaked at $1.52B in Q3 2013.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.